We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Microarray Technology Goes Beyond the Genome

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Microarray Technology Goes Beyond the Genome"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The expectation that microarray technology will play a large role in shaping the future of pharmaceutical development and diagnostics has increased due to new products and applications. 

Microarrays for gene expression have made a profound impact in the pharmaceutical and biomedical worlds.

Information from newer microarray technologies such as CGH, ChIP-on-chip, splice variants, and microRNAs, combined with gene expression data, can be applied to the drug discovery process enabling many exciting applications, such as finding cures for infectious diseases, discovering the mechanisms involved in cancer and finding treatments with fewer side effects.

The impact of these microarray applications on the healthcare and pharmaceutical industries is examined in a report, "Beyond Expression Arrays, Emerging Applications for Genomic Microarray Technology" from Beachhead, LLC 

The report reveals the market for the latest products and technologies as potentially one of the fastest growing segments of the life sciences market.

"We have been watching the development of microarray technologies for over a decade," said Richard Fisler, Director at Beachhead.

"At this time, the industry has evolved to a new level, and we wanted to present an in-depth view of the new approaches, the dynamics of market and the real applications."

The report is based on in-depth interviews of leading scientific researchers and biotechnology executives and presents the current applications and products contributing to the development of tools for clinical and pharmacological applications.

The commercial adoption for these technologies, given pharmaceutical objectives and trends, are presented.

Applications are addressed separately as each product must prove itself. The SNP market is the furthest along with the current market at about $400M with a potential for growth in the next 5 years to $1B.

Prior to the development of microarray technology, genetic expression experiments were conducted one gene at a time.

Microarray technology has provided molecular biologists, physicians, and researchers with a superhighway to genetic information. 

Microarray technology provides the means to monitor the whole genome on a single chip so that researchers can have a better picture of the interactions among thousands of genes simultaneously.

"The next obvious step was to go beyond gene expression and utilize microarray technology to enable whole ‘ome’ analysis for a variety of other applications, such as genotyping, comparative genomic hybridization, splice variants, ChIP arrays, and resequencing," stated Rich Fisler, Director at Beachhead.

"In our work at Beachhead, we have observed the emergence of new tools, products and applications for microarray technology," noted Gary Sams, Managing Director at Beachhead.

"We believe our clients and the marketplace are interested in a detailed analysis of these exciting new opportunities."